Views: 1,356 | Downloads:
193
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Effect of High Dose Ergocalciferol in Chronic Kidney Disease Patients with 25-Hydroxyvitamin D Deficiency
Trakarnvanich T 
,
Chalapipat O ,
Disthabanchong S ,
Kurathong S ,
Praditpornsilpa K ,
Stitchantrakul W ,
Chailurkit L
,
Chalapipat O ,
Disthabanchong S ,
Kurathong S ,
Praditpornsilpa K ,
Stitchantrakul W ,
Chailurkit L Objective: To evaluate 25 hydroxyvitamin D (25-OH-D) deficiency in a cohort of predialysis CKD patients and the treatment
effect and safety of high dose ergocalciferol supplement in predialysis CKD.
Material and Method: Fifty-six predialysis CKD patients who came for a regular visit at a single hospital with calculated
glomerular filtration rate < 60 mL/min/1.73 m2 were screened for 25-OH-D levels. Forty-four patients with 25-OH-D
deficiency were recruited into this prospective observational study that examined the effect of high dose oral ergocalciferol
supplementation. After eight weeks, 37 patients completed the follow-up and biochemical parameters were reevaluated and
analyzed.
Results: The mean 25-OH-D level of 56 patients was 25.6 + 8 ng/mL. Forty-four (78.5%) patients had 25-OH-D levels less
than 30 ng/mL and four (7.1%) had severe deficiency with the level less than 15 ng/mL. High dose ergocalciferol supplement
successively increased 25-OH-D levels in 35 (95%) patients. 25-OH-D levels increased significantly from 22 + 4.8 to 34.5
+ 10.8 ng/mL after eight weeks (p < 0.001). During the study period, there were no changes in serum calcium, phosphate, and
PTH. There was no other side effect associated with the treatment.
Conclusion: 25-OH-D deficiency were found in this cohort of predialysis CKD patients. Ergocalciferol was a safe and
effective supplement for the 25-OH-D in predialysis CKD.
Keywords: Vitamin D, Hyperparathyroidism, PTH, Ergocalciferol, 25-hydroxyvitamin D
effect and safety of high dose ergocalciferol supplement in predialysis CKD.
Material and Method: Fifty-six predialysis CKD patients who came for a regular visit at a single hospital with calculated
glomerular filtration rate < 60 mL/min/1.73 m2 were screened for 25-OH-D levels. Forty-four patients with 25-OH-D
deficiency were recruited into this prospective observational study that examined the effect of high dose oral ergocalciferol
supplementation. After eight weeks, 37 patients completed the follow-up and biochemical parameters were reevaluated and
analyzed.
Results: The mean 25-OH-D level of 56 patients was 25.6 + 8 ng/mL. Forty-four (78.5%) patients had 25-OH-D levels less
than 30 ng/mL and four (7.1%) had severe deficiency with the level less than 15 ng/mL. High dose ergocalciferol supplement
successively increased 25-OH-D levels in 35 (95%) patients. 25-OH-D levels increased significantly from 22 + 4.8 to 34.5
+ 10.8 ng/mL after eight weeks (p < 0.001). During the study period, there were no changes in serum calcium, phosphate, and
PTH. There was no other side effect associated with the treatment.
Conclusion: 25-OH-D deficiency were found in this cohort of predialysis CKD patients. Ergocalciferol was a safe and
effective supplement for the 25-OH-D in predialysis CKD.
Keywords: Vitamin D, Hyperparathyroidism, PTH, Ergocalciferol, 25-hydroxyvitamin D
Download:
PDF